News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enanta Pharmaceuticals, Inc. Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)


3/5/2014 7:26:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES